Recombinant ACE2 - Opportunities and Challenges in COVID-19 Treatment

Rahul Sandhu; Mandeep Kaur; Akriti Aggarwal

doi:10.2174/0118715265298816240321045741

Recombinant ACE2 - Opportunities and Challenges in COVID-19 Treatment

Infect Disord Drug Targets. 2024 Apr 18. doi: 10.2174/0118715265298816240321045741. Online ahead of print.

Authors

Rahul Sandhu¹, Mandeep Kaur², Akriti Aggarwal³

Affiliations

¹ Department of General Surgery, Armed Forces Medical College, Pune, Maharashtra, 411040, India.
² Government Medical College, Patiala, Punjab, India.
³ Microbiology, Senior Resident, AIIMS Bathinda, India.

PMID: 38639270
DOI: 10.2174/0118715265298816240321045741

Abstract

It was in 2019 that the world experienced the devastation caused by SARS-COV-2, contributing to a large number of deaths. This contagious virus not only challenged the health care system but has also hit the economy very badly. There has been a lot of research on effective vaccine development, and there has been some success in the same, but no effective antiviral drugs are available in the market. No doubt vaccination can prevent the disease, but it doesn't have the potential to cure an infected person, for which there is a dire need to develop some effective drug. Angiotensin convertase enzyme 2 (ACE2) played a substantial role in SARS-COV2 pathogenesis and thus has gained much attention during the pandemic. Moreover, it has opened up new avenues for the cure of COVID-19.

Keywords: SARS-COV2; COVID19; ACE2 downregulation; recombinant ACE2.